ACADIA Pharmaceuticals Inc. (ACAD)

Ausiliatrice Cristiano
Agosto 10, 2017

We have $37.87 PT which if reached, will make NASDAQ:ACAD worth $381.60 million more. Geduld E E acquired 15,215 shares as Acadia Pharm (ACAD)'s stock declined 29.10%. Teachers Advisors LLC's holdings in ACADIA Pharmaceuticals were worth $4,298,000 as of its most recent filing with the SEC. The Harvey Capital Management Inc holds 251,825 shares with $7.26 million value, down from 332,825 last quarter. Fidelity Management and Research Company is the second biggest holder with 18 million shares now valued at 625.64 million whilst Vanguard Group Inc has 7 million shares valued at 256.81 million. OppenheimerFunds Inc. boosted its stake in ACADIA Pharmaceuticals by 3.6% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company's stock valued at $155,000 after buying an additional 510 shares during the period. Norges Bank bought a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $24,050,000. Institutional investors own 97.16% of the company's stock. Mutual Of America Cap Management Llc reported 0.04% of its portfolio in ACADIA Pharmaceuticals Inc. The firm's 50-day moving average is $28.71 and its 200-day moving average is $32.08.

The firm also spoke of its survey of 100 physicians last July, which showed a larger market opportunity and more bullish physician attitude to prescribing Nuplazid than it had modeled at that time.

Reviewing the second quarter results, HC Wainwright noted the company reported net sales of $30.5 million, which includes a $3.5 million one-time adjustment. (NASDAQ:ACAD). Moreover, Sg Americas Securities Ltd has 0.02% invested in ACADIA Pharmaceuticals Inc. During the same quarter a year ago, the business posted ($0.63) EPS. Looking out over the past year, company shares have been recorded -17.56% off the 52 week high and 62.77% away from the low over the same period.Covering sell-side analysts have recently weighed in on shares of ACADIA Pharmaceuticals Inc. Transamerica Advsr Inc has 0% invested in ACADIA Pharmaceuticals Inc. "(NASDAQ:ACAD)" was published by Stock Observer and is the property of of Stock Observer. If you are reading this article on another site, it was illegally stolen and republished in violation of USA and global trademark & copyright law. The legal version of this news story can be read at BidaskClub upgraded shares of ACADIA Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, July 24th.

In addition to Zacks Investment Research reporting its stock price target, a total of 10 brokers have issued a report on the company. Based on 3 analysts polled by TipRanks in the last 3 months, all 3 rate a Buy on Acadia stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company.

Following Acadia's announcement, Cowen & Company told investors this morning that it was reaffirming an Outperform rating on the company's stock - while lifting its price target from $42.00 to $46.00.

In other news, EVP Glenn Baity sold 1,903 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was unloaded at a price range of of $30.00, amounting to $1,142,910.00. Following the transaction, the executive vice president now directly owns 109,253 shares in the company, valued at $3,277,590. Winslow Evans And Crocker Incorporated owns 3,500 shares. The Return on Equity ratio of ACADIA Pharmaceuticals Inc. The Firm is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus infection.

Altre relazioni OverNewsmagazine

Discuti questo articolo